Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNeuropace Inc

Neuropace Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
12.15 USD -0.37 ( 2.96%)
Last update at 2026-11-12T15:32:00Z
VOLUME
11543
Market Cap
216.62M

Momentum Score

…

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.09
Low
12.67
High
52 Week Price Range
3.80
Low
18.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
12.52
Dividend Yield
-
Revenue TTM
69.07M
Revenue Per Share
2.59
Gross Profit TTM
32.49M
Debt / Equity
3.51
ROE
-150.63%
Net Debt
54.34M
ROCE
-44.62%
Diluted EPS TTM
-1.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -47.08M -36.08M -24.28M -29.97M
Net income -53.37M -38.11M -35.98M -40.74M
Selling general administrative 51.34M 38.96M 27.63M 30.20M
Gross profit 32.49M 33.44M 30.27M 26.46M
Reconciled depreciation 2.99M 0.30M 0.31M 0.42M
Ebit -40.79M -23.74M -13.05M -22.03M
Ebitda -39.55M -28.37M -12.48M -20.07M
Depreciation and amortization 1.24M -4.64M 0.57M 1.96M
Non operating income net other 1.24M -4.93M - -
Operating income -40.79M -23.74M -13.05M -22.03M
Other operating expenses 86.31M 68.92M 54.19M 59.00M
Interest expense 7.53M 7.41M 11.49M 9.48M
Interest income 1.58M 0.45M 0.04M 0.26M
Net interest income -5.95M -6.96M -11.45M -9.22M
Income tax expense 6.29M 2.03M 11.70M 10.77M
Total revenue 45.52M 45.18M 41.14M 36.97M
Total operating expenses 73.29M 57.17M 43.32M 48.49M
Cost of revenue 13.03M 11.75M 10.87M 10.51M
Total other income expense net -6.29M -12.34M -11.23M -7.94M
Net income from continuing ops -47.08M -36.08M -24.28M -29.97M
Net income applicable to common shares -47.08M -36.08M -24.05M -29.97M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 107.65M 114.11M 133.56M 55.95M 21.09M
Other current assets 2.74M 3.11M 2.32M 1.18M 1.25M
Total liab 87.00M 79.33M 60.06M 203.78M 150.44M
Total stockholder equity 20.65M 34.78M 73.50M -147.83M -129.35M
Deferred long term liab - 0.35M 0.91M 0.48M -
Other current liab 11.18M 7.41M 7.92M 6.60M 4.72M
Common stock 0.03M 0.03M 0.02M 0.00M 0.00M
Capital stock 0.03M 0.03M 0.02M 0.00M 0.00M
Retained earnings -503.81M -470.85M -423.77M -387.69M -363.64M
Other liab - - 0.91M 1.57M 1.73M
Other assets - 0.49M 134.31M 0.87M 0.03M
Cash 18.06M 6.61M 19.19M 26.39M 4.12M
Total current liabilities 16.23M 10.98M 9.30M 9.60M 75.15M
Current deferred revenue 1.09M - - - 6.73M
Net debt 54.34M 63.16M 30.66M 26.47M 58.68M
Short term debt 1.63M 1.42M - 2.04M 62.80M
Short long term debt - - - 2.04M 62.80M
Short long term debt total 72.39M 69.77M 49.85M 52.86M 62.80M
Other stockholder equity 524.43M 506.71M 363.96M 239.83M 234.29M
Property plant equipment - 1.06M 0.60M 0.52M 0.81M
Total current assets 92.72M 97.71M 132.82M 54.56M 20.26M
Net tangible assets - 34.78M 73.50M -147.83M -129.35M
Short term investments 48.40M 70.80M 96.40M 11.69M 0.97M
Net receivables 12.31M 7.48M 7.09M 8.39M 6.02M
Long term debt 56.95M 52.91M 49.85M 50.82M -
Inventory 11.21M 9.71M 7.82M 6.91M 7.90M
Accounts payable 2.33M 2.15M 1.38M 0.95M 0.90M
Accumulated other comprehensive income 0.00M -1.11M -0.27M 0.03M 0.00M
Common stock total equity - 0.03M 0.02M - -
Retained earnings total equity - -470.85M -423.77M - -
Non currrent assets other 0.40M 0.49M 0.14M 0.87M 0.03M
Deferred long term asset charges - 0.35M - - -
Non current assets total 14.93M 16.39M 0.75M 1.39M 0.83M
Capital lease obligations 15.44M 16.86M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 24.40M -85.01M -10.71M 4.08M
Change to liabilities 0.63M 1.95M -0.01M -0.08M
Total cashflows from investing activities 23.80M -85.40M -10.77M 3.62M
Net borrowings - -4.09M 24.46M 21.33M
Total cash from financing activities 0.49M 102.53M 55.01M 21.37M
Change to operating activities -2.91M -0.26M -0.36M 2.48M
Net income -47.08M -36.08M -24.28M -29.97M
Change in cash -12.58M -7.45M 22.63M -0.04M
Begin period cash flow 19.31M 26.76M 4.12M 4.16M
End period cash flow 6.73M 19.31M 26.76M 4.12M
Total cash from operating activities -36.87M -24.58M -21.61M -25.03M
Issuance of capital stock 0.00M 109.09M 31.70M 0.00M
Depreciation 2.99M 0.30M 0.31M 0.42M
Change to inventory -2.13M -1.16M 0.67M -1.64M
Change to account receivables -0.39M 1.30M -2.38M -0.75M
Sale purchase of stock 0.55M 106.62M - -
Other cashflows from financing activities -0.41M -2.47M 97.13M 3.62M
Change to netincome 10.88M 9.77M 0.93M 2.08M
Capital expenditures 0.60M 0.38M 0.06M 0.47M
Change receivables -0.39M 1.30M - -
Cash flows other operating 0.70M -0.92M - -
Cash and cash equivalents changes -12.58M -7.45M - -
Change in working capital -4.79M 0.37M -2.07M 0.01M
Stock based compensation 8.35M 4.29M 1.38M 1.44M
Other non cash items 3.67M 1.07M 2.86M 4.02M
Free cash flow -37.47M -24.96M -21.67M -25.49M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NPCE
Neuropace Inc		 -0.37
2.96%		 12.15 - - 5.85 18.45 5.91 -16.94
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Neuropace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

455 North Bernardo Avenue, Mountain View, CA, United States, 94043

650-237-2700

https://www.neuropace.com

181

Name Title Year Born
Mr. Michael L. Favet Pres, CEO & Director 1970
Ms. Irina Ridley Gen. Counsel & Corp. Sec. 1986
Dr. Martha J. Morrell Chief Medical Officer 1957
Ms. Rebecca L. Kuhn CFO, VP of Fin. & Admin. and Assistant Sec. 1961
Ms. Chi Nguyen VP of Marketing 1977
Mr. Mark S. Saxton VP of Sales 1965
Ms. Irene Thomas VP of HR 1969
Mr. Andre G. Marquette Chief Commercial Officer NA
Mr. Joel D. Becker CEO, President & Director 1968
Ms. Rebecca L. Kuhn CFO, VP of Finance & Administration and Assistant Secretary 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…